Contract research firm Parexel is said to garner takeover interest from Private equity giant EQT and a consortium of three other buyout majors.
A consortium of Cinven, Centerbridge and GTCR is working on a bid for the contract research organization, according to traders, who cited a Bloomberg report.
Parexel is said to have received interest from about 10 parties.
Bloomberg reported in April Parexel’s PE owner Pamplona Capital Management was exploring a sale of the company in a deal that could value Parexel at about $9B including debt.
The potential sale comes after some other big deals for CROs earlier this year including Thermo Fisher’s (NYSE:TMO) planned $17B deal for PPD (NASDAQ:PPD) and Icon PLC’s agreement to purchase PRA Health (NASDAQ:PRAH) for about $12B.
Source: Seeking Alpha
Can’t stop reading? Read more
Pimco, KKR, and Bain circle John Lewis card issuer NewDay in £1.7bn buyout race
Pimco, KKR, and Bain circle John Lewis card issuer NewDay in £1.7bn buyout race NewDay Group, one...
KKR turns to direct lenders for €1.1bn unitranche package to finance Karo Healthcare acquisition
KKR turns to direct lenders for €1.1bn unitranche package to finance Karo Healthcare acquisition...
Coller Capital hires Alexander Ordon to lead private wealth secondaries push in Australia and New Zealand
Coller Capital hires Alexander Ordon to lead private wealth secondaries push in Australia and New...